1. In this case-control study, younger age of onset of non-alcoholic fatty liver disease (NAFLD) was associated with greater cancer risk, with greatest risk for digestive and pulmonary cancers. Evidence rating level: 3 (Average) The prevalence of non-alcoholic fatty liver disease (NAFLD) is projected to reach 33.5% of the global population by 2030, as the
Compared to placebo, patients using once-daily oral HU6 100 mg, HU6 300 mg, and HU6 450 mg experienced significant changes in liver fat, volume, and whole-body adiposity after 61 days of treatment.
Obesity rates in the US have skyrocketed, and so has the prevalence of several comorbid gastrointestinal and hepatic diseases - not all patients know their risks or have the financial means to take preventative measures.